Discover 1,441 paid clinical trials in Kent, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,441
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
for
Plaque Psoriasis
Location: Mill Creek WA, Edmonton, Walnut Creek CA, Fremont CA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 12 - 17
Code: NCT06979453
Phase3, Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
for
Plaque Psoriasis
Location: Mill Creek WA, Surrey, Portland OR, Nanaimo, Kelowna,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 40+
Code: NCT07116967
Phase3, Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
for
Lichen Planopilaris
Location: Mill Creek WA, Portland OR, Edmonton, Sacramento CA,
Sponsor: Priovant Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07532603
Phase2, Phase3, Recruiting
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
mGain - sEMG-based Gamified Therapy for Improved Upper Limb Rehabilitation
for
Upper Limb Weakness Due to Central Neurologic Injury,
Location: Edmonds WA
Sponsor: Orthocare Innovations, LLC
Sex: All
Age: 18+
Code: NCT06023316
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFO
for
Stroke
Location: Edmonds WA, Troy MI
Sponsor: Orthocare Innovations, LLC
Sex: All
Age: 18+
Code: NCT05619484
Phase2, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
for
Non-Small-Cell Lung Cancer,
Location: Edmonds WA, Vancouver, Calgary, Sacramento CA,
Sponsor: ArriVent BioPharma, Inc.
Sex: All
Age: 18+
Code: NCT07185997
Phase3, Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.